5 Best Small Cap Pharma Stocks to Buy

3. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Number of Hedge Fund Investors in Q1 2023: 23

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) sells treatments for nervous system disorders including epilepsy and Attention Deficit Hyperactivity Disorder (ADHD). The shares are down 4.2% over the past 12 months but are still rated Buy on average with several Strong Buy ratings as well.

As of March 2023, 23 of the 943 hedge fund portfolios studied by Insider Monkey had held Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s shares. Steven Boyd’s Armistice Capital is the largest investor among these, courtesy of its $157 million investment.

Follow Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)